Abstract

The major objective of this Immunology Core is to coordinate and provide essential tissue/cell research material and information of patients' HLA genotypes to laboratories involved in this HPV Vaccine Program. The significant function of this Immunology Core is that through a centralized distribution of specimens, each Project will be ensured to receive research material of comparable quality. Furthermore, centralizing and coordinating patient specimens and clinical information by this Core will substantially reduce the overall cost and manpower needs. Specifically, three major efforts will be provided from this Immunology Core. First, this facility will process patient blood and isolate peripheral blood mononuclear cells (PBMCs). Second, this facility will bank fresh specimens including plasma, serum, PBMCs, cervical secretions and EBV-immortalized lymphocytes, and will also bank cervical cancer specimens from patients. Third, this facility will obtain and file the information of HLA genotypes of patients in this clinical trial.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI048203-02
Application #
6473466
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2001-07-01
Project End
2002-06-30
Budget Start
Budget End
Support Year
2
Fiscal Year
2001
Total Cost
Indirect Cost

  Institution

Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218

  Publications

Yang, Rongcun; Wheeler, Cosette M; Chen, Xiaojiang et al. (2005) Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol 79:6741-50
Yang, Rongcun; Murillo, Francisco Martinez; Delannoy, Michael J et al. (2005) B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 174:7912-9
Pinto, Ligia A; Castle, Philip E; Roden, Richard B et al. (2005) HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 23:3555-64
Yang, Rongcun; Murillo, Francisco Martinez; Lin, Ken-Yu et al. (2004) Human papillomavirus type-16 virus-like particles activate complementary defense responses in key dendritic cell subpopulations. J Immunol 173:2624-31
Yang, Rongcun; Murillo, Francisco Martinez; Cui, Hengmi et al. (2004) Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol 78:11152-60
Peng, Shiwen; Ji, Hongxiu; Trimble, Cornelia et al. (2004) Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 78:8468-76
Kim, Tae Woo; Lee, Jin Hyup; Hung, Chien-Fu et al. (2004) Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 78:4638-45
Cheng, W F; Hung, C F; Lin, K Y et al. (2003) CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 10:1311-20
Yang, Rongcun; Yutzy 4th, William H; Viscidi, Raphael P et al. (2003) Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem 278:12546-53
Roden, R B; Day, P M; Bronzo, B K et al. (2001) Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. J Virol 75:10493-7